Evidence map›Paper›PMID 35910326›Full record

ArticleJournal of epilepsy research2022

Perampanel as First Add-On Therapy in Patients with Focal-Onset Seizures in the FAME Trial:

Ji Hyun Kim, Dong Wook Kim, Sang Kun Lee, Dae-Won Seo, Ji Woong Lee, Min Young Kim, Sang Ahm Lee

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of epilepsy research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Ji Hyun KimDepartment of Neurology, Korea University Guro Hospital, Seoul, Korea.
Dong Wook KimDepartment of Neurology, Konkuk University School of Medicine, Seoul, Korea.
Sang Kun LeeDepartment of Neurology, Seoul National University Hospital, Seoul, Korea.
Dae-Won SeoDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ji Woong LeeEisai Korea Inc., Seoul, Korea.
Min Young KimEisai Korea Inc., Seoul, Korea.
Sang Ahm LeeDepartment of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Eisai (South Korea) · KRAsan Medical Center · KRKonkuk University · KRKorea University Medical Center · KRSamsung Medical Center · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: FAME (Fycompa Methods: Patients were stratified by low- (4, 6 mg/day) versus high- (8, 10, 12 mg/day) dose maintenance perampanel, perampanel added to first- versus second-line ASM monotherapy, and concomitant background ASM monotherapy and perampanel dose. The primary endpoint was the proportion of patients with a ≥50% reduction in total seizure frequency during the 24-week maintenance period. Safety was assessed by the descriptive incidence of treatment-emergent adverse events (TEAEs). Results: In Conclusions:

Indexed as

AMPA receptorfocalgeneralizedPerampanelSeizures

Identifiers

PMID35910326
PMCPMC9289376
OpenAlexW4283793528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.